Table 4 Antidiabetic and antihypertensive drugs use and combinations of a group of patients with type 2 diabetes mellitus and chronic kidney disease in Colombia

Metformin

3019

20.5

Metformin + dipeptidyl peptidase-4 inhibitor

1976

13.4

Metformin + dipeptidyl peptidase-4 inhibitor + Insulin

1500

10.2

No treatment for diabetes mellitus

1303

8.9

Dipeptidyl peptidase-4inhibitor + Insulin

1052

7.1

Dipeptidyl peptidase-4 inhibitor

934

6.3

Insulin

741

5

Metformin + dipeptidyl peptidase-4 inhibitor + Sodium-Glucose Transporter 2 Inhibitors + Insulin

639

4.3

Metformin + dipeptidyl peptidase-4 inhibitor + Sodium-Glucose Transporter 2 Inhibitors

427

2.9

Metformin + Sulfonylureas

412

2.8

48 other combinations

2719

18.5

Antihypertensive drugs alone or in associations

Frequency

%

ARBs

1611

10.9

Without antihypertensive therapy

1518

10.3

ARBs + Calcium channel blocker

1170

7.9

ARBs + Calcium channel blocker + Hydrochlorothiazide + Furosemide

902

6.1

ARBs + Calcium channel blocker + β-blocker + Hydrochlorothiazide + Furosemide

792

5.4

ACEis

761

5.2

ARBs + Calcium channel blocker + Hydrochlorothiazide

659

4.5

ARBs + β-blocker

621

4.2

ARBs + Calcium channel blocker + β-blocker

588

4

ARBs + β-blocker + Hydrochlorothiazide + Furosemide

532

3.6

ARBs + Hydrochlorothiazide + Furosemide

528

3.6

ARBs + Hydrochlorothiazide

488

3.3

β-blocker

292

2

ARBs + Calcium channel blockers + β-blocker + Hydrochlorothiazide

277

1.9

ARBs + Calcium channel blockers + β-blocker + Hydrochlorothiazide + Furosemide +

226

1.5

Mineralocorticoid receptor antagonist

ARBs + β-blocker + Hydrochlorothiazide + Furosemide + Mineralocorticoid receptor antagonist

185

1.3

ARBs + β-blocker + Hydrochlorothiazide

181

1.2

Calcium channel blocker

174

1.2

ACEis + β-blocker

154

1

ACEis + Hydrochlorothiazide

150

1

Other 76 combinations

2913

19.8